Abstract
Objectives
In this article the state of art the of prostate cancer (Pca) imaging and non-surgical salvage treatments (STs) is surveyed in order to explore the impact of imaging findings on the identification of radiorecurrent Pca after external beam radiotherapy (EBRT).
Methods
A computerised search was performed to identify all relevant studies in Medline up to 2012. Additional articles were extracted based on recommendations from an expert panel of authors.
Results
Definitive EBRT for Pca is increasingly used as treatment. After radiorecurrent Pca, non-surgical STs are emerging and shifting from investigational status to more established therapeutic options. Therefore, several scientific societies have published guidelines including clinical and imaging recommendations, even if the timing, efficacy and long-term toxicity of these STs have to be established. In some measure, accurately delineating the location and the extent of cancer is critical in selecting target lesions and in identifying patients who are candidates for STs. However, there is increasing awareness that anatomical approaches based on measurements of tumour size have substantial limitations, especially for tumours of unknown activity that persist or recur following irradiation
Conclusions
To date, the main focus for innovations in imaging is the combination of excellence in anatomical resolution with specific biological correlates that depict metabolic processes and hallmarks at the tumour level. The emergence of new molecular markers could favour the development of methods that directly determine their presence, thereby improving tumour detection.
Key Points
• Imaging may influence therapeutic decisions during non-surgical STs.
• MRI findings correlate with parametric maps derived from multiple functional techniques.
• Non-surgical salvage treatments allow local tumour control in patients with radiorecurrent PCa.
Similar content being viewed by others
References
Potosky AL, Davis WW, Hoffman RM (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96:1358–1367
D’Amico AV, Cote K, Loffredo M (2003) Pre-treatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 169:1320–1324
Hanlom AL, Moore DF, Hanks GE (1998) Modelling post-radiation PSA levels kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma. Cancer 83:130–134
Zietman AL, Christodouleas JP, Shipley WU (2005) PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure. Int J Radiat Oncol Biol Phys 62:714–718
Horwitz EM, Thames HD, Kuban DA (2005) Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated by external beam radiation alone: a multi-institutional pooled analysis. J Urol 173:797–802
Abramowitz MC, Li T, Buyyounouski MK (2008) The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 112:55–60
D’Amico AV, Chen MH, de Castro M et al (2012) Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol 13:189–195
Hancock SL, Cox RS, Bagshaw MA (1995) Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J Urol 154:1412–1417
Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ (2010) Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int 105:191–201
Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ (2011) Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int 108:1074–1085
Porten SP, Cooperberg MR, Carroll PR (2010) The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int 105:472–475
Lindner U, Lawrentschuk N, Trachtenberg J (2010) Image guidance for focal therapy of prostate cancer. World J Urol 28:727–734
Tan CH, Wang J, Kundra V (2011) Diffusion weighted imaging in prostate cancer. Eur Radiol 21:593–603
Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, Fleischmann A, Vermathen P, Studer UE (2009) Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 55:761–769
Rouvière O, Papillard M, Girouin N, Boutier R, Rabilloud M, Riche B, Mège-Lechevallier F, Colombel M, Gelet A (2012) Is it possible to model the risk of malignancy of focal abnormalities found at prostate multiparametric MRI? Eur Radiol 22:1149-1157
Rouvière O, Vitry T, Lyonnet D (2010) Imaging of prostate cancer local recurrences: why and how? Eur Radiol 20:1254–1266
Akin O, Gultekin DH, Vargas HA, Zheng J, Moskowitz C, Pei X, Sperling D, Schwartz LH, Hricak H, Zelefsky MJ (2011) Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 9:1970–1978
Westphalen AC, Koff WJ, Coakley FV, Muglia VF, Neuhaus JM, Marcus RT, Kurhanewicz J, Smith-Bindman R (2011) Prostate cancer: prediction of biochemical failure after external-beam radiation therapy—Kattan nomogram and endorectal MR imaging estimation of tumor volume. Radiology 1:477–486
Pucar D, Shukla-Dave A, Hricak H (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy ñ initial experience. Radiology 236:545–553
Coakley FV, The HS, Qayyum A (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233:441–448
Westphalen AC, Coakley FV, Roach M 3rd, McCulloch CE, Kurhanewicz J (2010) Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 6:485–492
Arumainayagam N, Kumaar S, Ahmed HU, Moore CM, Payne H (2010) Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int 106:991–997
Franiel T, Hamm B, Hricak H (2011) Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol 21:616–626
Haider MA, Chung P, Sweet J (2008) Dynamic contrast enhanced magnetic resonance imaging for localisation of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70:425–430
Kim CK, Park BK, Park W, Kim SS (2010) Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging 35:246–252
Martino P, Scattoni V, Galosi AB, Consonni P, Trombetta C, Palazzo S, Maccagnano C, Liguori G, Valentino M, Battaglia M, Barozzi L (2011) Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU. World J Urol 29:595–605
Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, Claussen CD, Stenzl A, Schlemmer HP, Schilling D (2012) MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 30:213-218
Turkbey B, Xu S, Kruecker J, Locklin J, Pang Y, Bernardo M, Merino MJ, Wood BJ, Choyke PL, Pinto PA (2011) Documenting the location of prostate biopsies with image fusion. BJU Int 107:53–57
Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendörfer T, Huber J, Zogal P, Teber D, Pahernik S, Roethke M, Zamecnik P, Roth W, Sakas G, Schlemmer HP, Hohenfellner M (2011) A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 186:2214–2220
Schouten MG, Bomers JG, Yakar D, Huisman H, Rothgang E, Bosboom D, Scheenen TW, Misra S, Fütterer JJ (2012) Evaluation of a robotic technique for transrectal MRI-guided prostate biopsies. Eur Radiol 22:476–483
Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57:108–111
Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, Freschi M, Fazio F, Messa C (2008) [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 35:1065–1073
Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN (2011) The role of choline positron tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 59:51–60
Pucar D, Sella T, Schöder H (2008) The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 18:87–97
Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, Schuster T, Geinitz H, Treiber U, Schwaiger M (2008) The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18–23
Núñez R, Erwin WD, Wendt RE 3rd, Stachowiak A, Mar M, Stevens D, Madewell JE, Yeung HW, Macapinlac HA (2010) Acquisition parameters for oncologic imaging with a new SPECT/multislice CT scanner. Mol Imaging Biol 12:110–138
Brawer MK (2002) Radiation therapy failure in prostate cancer patients: risk factors and methods of detection. Rev Urol 4(Suppl 2):S2–S11
Grossfeld GD, Li YP, Lubeck DP, Broering JM, Mehta SS, Carroll PR (2002) Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 168:530–535
Moman MR, van den Berg CA, Boeken Kruger AE, Battermann JJ, Moerland MA, van der Heide UA, van Vulpen M (2010) Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int J Radiat Oncol Biol Phys 76:741–746
Wang H, Vees H, Miralbell R, Wissmeyer M, Steiner C, Ratib O, Senthamizhchelvan S, Zaidi H (2009) 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol 93:220–225
Weber DC, Wang H, Cozzi L, Dipasquale G, Khan HG, Ratib O, Rouzaud M, Vees H, Zaidi H, Miralbell R (2009) RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study. Radiat Oncol 4:34–39
Vavassori A, Jereczek-Fossa BA, Beltramo G (2010) Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases. Tumori 96:71–75
Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, Zerini D, Gherardi F, Ascione C, Bossi-Zanetti I, Mauro R, Bregantin A, Bianchi LC, De Cobelli O, Orecchia R (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82:889–897
Finley DS, Belldegrun AS (2011) Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications. Curr Urol Rep 12:209–215
Mouraviev V, Spiess PE, Jones JS (2012) Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol 61:1204-1211
Lukka H, Waldron T, Chin J, Mayhew L, Warde P, Winquist E, Rodrigues G, Shayegan B (2011) Genitourinary Cancer Disease Site Group of Cancer Care Ontario’s Program in evidence-based care. High-intensity focused ultrasound for prostate cancer: a systematic review. Clin Oncol (R Coll Radiol) 23:117–127
Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, Allen C, Emberton M (2008) The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int 102:786–792
Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouvière O, Curiel L, Janier M, Vallancien G (2004) Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63:625–629
Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon JY, Gelet A (2009) Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 55:640–647
Berge V, Baco E, Karlsen SJ (2010) A prospective study of salvage high-intensity focused ultrasound for locally radiorecurrent prostate cancer: early results. Scand J Urol Nephrol 44:223–227
Berge V, Baco E, Dahl AA, Karlsen SJ (2011) Health-related quality of life after salvage high-intensity focused ultrasound (HIFU) treatment for locally radiorecurrent prostate cancer. Int J Urol 18:646–651
Nathan TR, Whitelaw DE, Chang SC, Lees WR, Ripley PM, Payne H, Jones L, Parkinson MC, Emberton M, Gillams AR, Mundy AR, Bown SG (2002) Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 168:1427–1432
Weersink RA, Bogaards A, Gertner M (2005) Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities. J Photochem Photobiol B 79:211–222
Trachtenberg J, Weersink RA, Davidson SR, Haider MA, Bogaards A, Gertner MR, Evans A, Scherz A, Savard J, Chin JL, Wilson BC, Elhilali M (2008) Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 02:556–562
Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey SA, Scherz A, Gertner MR, Yue C, Appu S, Aprikian A, Savard J, Wilson BC, Elhilali M (2007) Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 178:1974–1979
Ahmed HU, Moore C, Lecornet E, Emberton M (2010) Focal therapy in prostate cancer: determinants of success and failure. J Endourol 24:819–825
Chen JC, Moriarty JA, Derbyshire JA, Peters RD, Trachtenberg J, Bell SD, Doyle J, Arrelano R, Wright GA, Henkelman RM, Hinks RS, Lok SY, Toi A, Kucharczyk W (2000) Prostate cancer: MR imaging and thermometry during microwave thermal ablation-initial experience. Radiology 214:290–297
Lancaster C, Toi A, Trachtenberg J (1999) Interstitial microwave thermoablation for localized prostate cancer. Urology 53:828–831
Trachtenberg J, Chen J, Kucharczyk W, Toi A, Lancaster C (1999) Microwave thermoablation for localized prostate cancer after failed radiation therapy: role of neoadjuvant hormonal therapy. Mol Urol 3:247–250
McCann C, Kumaradas JC, Gertner MR, Davidson SR, Dolan AM, Sherar MD (2003) Feasibility of salvage interstitial microwave thermal therapy for prostate carcinoma following failed brachytherapy: studies in a tissue equivalent phantom. Phys Med Biol 48:1041–1052
Shariat SF, Raptidis G, Masatoschi M, Bergamaschi F, Slawin KM (2005) Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate 65:260–267
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gravina, G.L., Tombolini, V., Di Staso, M. et al. Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know?. Eur Radiol 22, 2848–2858 (2012). https://doi.org/10.1007/s00330-012-2546-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-012-2546-7